Abstract 1334: Drug-Coated Balloon versus Bare-Metal Stent For Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis
Stroke: Vascular and Interventional Neurology · 18.10.2026 · 6 (Suppl_1)
DOI: 10.1161/svi270000_1334 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Stroke: Vascular and Interventional Neurology, erschienen am 18.10.2026. Verfasst von W. Lee und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Restenosis following bare-metal stent (BMS) implantation remains a major limitation of endovascular treatment for symptomatic intracranial atherosclerotic stenosis (sICAS) and contributes to recurrent ischemic events. Drug-coated balloons (DCBs) inhibit neointimal hyperplasia without leaving a permanent implant and may reduce restenosis risk. We performed a systematic review and meta-analysis comparing the efficacy and safety of DCB versus BMS in patients with sICAS.
Methods
A systematic search of PubMed, Embase, and Web of Science identified comparative studies evaluating DCB versus BMS for sICAS. Randomized controlled trials (RCTs) and comparative observational studies were included. The primary endpoint was angiographic restenosis. Secondary endpoints included symptomatic restenosis and recurrent ischemic events. Random-effects meta-analysis using the Hartung-Knapp-Sidik-Jonkman method was performed to estimate pooled odds ratios (OR) with 95% confidence intervals (CI). Between-study heterogeneity was assessed using I² statistics.
Results
Six studies (2 RCTs and 4 comparative observational studies) comprising 647 patients (DCB: 293; BMS: 354) were included. DCB significantly reduced angiographic restenosis compared with BMS (25/293 vs 114/354; OR 0.21, 95% CI 0.12-0.35; P=0.0006; I²=0%), representing a 79% relative reduction in odds. Recurrent ischemic events were also significantly lower in the DCB group (11/327 vs 45/386; OR 0.27, 95% CI 0.17-0.42; P=0.0007; I²=0%). Symptomatic restenosis demonstrated a favorable trend toward DCB (4/162 vs 20/196; OR 0.25, 95% CI 0.05-1.24; P=0.07; I²=0%), though statistical significance was not reached. Across all outcomes, heterogeneity was minimal, indicating consistent treatment effects across study designs and centers.
Conclusion
In patients with symptomatic intracranial atherosclerotic stenosis, drug-coated balloon angioplasty is associated with significantly lower rates of angiographic restenosis and recurrent ischemic events compared with bare-metal stenting, with highly consistent effects across studies. Although symptomatic restenosis reduction did not reach statistical significance, the magnitude of effect favored DCB. These findings support DCB as a promising endovascular strategy for sICAS and warrant further multicenter randomized evaluation against contemporary medical management.
Zitieren
APA
Lee, W., Tran, T., Maciel, R., Suppakitjanusant, P., Vu, A., Raz, E., Yedavalli, V., Scarcia, L., Regenhardt, R., & Dmytriw, A. (2026). Abstract 1334: Drug-Coated Balloon versus Bare-Metal Stent For Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis. Stroke: Vascular and Interventional Neurology, 6(Suppl_1). https://doi.org/10.1161/svi270000_1334
Vancouver
Lee W, Tran T, Maciel R, Suppakitjanusant P, Vu A, Raz E, et al. Abstract 1334: Drug-Coated Balloon versus Bare-Metal Stent For Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis. Stroke: Vascular and Interventional Neurology. 2026;6(Suppl_1). doi:10.1161/svi270000_1334
BibTeX
@article{Lee2026,
author = {Lee, W. and Tran, T. and Maciel, R. and Suppakitjanusant, P. and Vu, A. and Raz, E. and Yedavalli, V. and Scarcia, L. and Regenhardt, R. and Dmytriw, A.},
title = {Abstract 1334: Drug-Coated Balloon versus Bare-Metal Stent For Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis},
journal = {Stroke: Vascular and Interventional Neurology},
year = {2026},
volume = {6},
number = {Suppl_1},
doi = {10.1161/svi270000_1334}
}
EUVIMED